Adapted RPM-08 for Substance Use Disorder in Pakistan
Effect of Adapted Relapse Prevention Module (RPM-08) for Patients With Substance Use Disorder in Pakistan
1 other identifier
interventional
70
1 country
1
Brief Summary
The goal of this clinical trial is to learn if a culturally adapted Relapse Prevention Module (RPM-08) can reduce relapse risk in people with substance use disorders in Pakistan. The study also examines whether the adapted intervention is effective over time. The main questions it aims to answer are: Does the adapted RPM-08 reduce relapse risk compared to usual treatment? Are the effects of the intervention maintained after a follow-up period? Researchers compared participants who received the adapted RPM-08 along with usual treatment to those who received usual treatment only to see if the intervention improves relapse outcomes. Participants will: Attend eight structured group sessions over eight weeks Receive usual treatment provided by the rehabilitation center Complete questionnaires at baseline, after the intervention, and at follow-up
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 4, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 13, 2024
CompletedFirst Submitted
Initial submission to the registry
April 20, 2026
CompletedFirst Posted
Study publicly available on registry
April 27, 2026
CompletedApril 27, 2026
April 1, 2026
2 months
April 20, 2026
April 20, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Relapse Risk
Relapse risk was assessed using the Advance Warning of Relapse (AWARE) questionnaire to evaluate changes in relapse-related warning signs among participants across different assessment time points.
Baseline, post-intervention (8 weeks), and 45-day follow-up
Secondary Outcomes (1)
Change in Relapse Risk Over Time
Baseline, post-intervention (8 weeks), and 45-day follow-up
Study Arms (2)
RPM-08 + Treatment-As-Usual
EXPERIMENTALParticipants in this arm received the adapted Relapse Prevention Module (RPM-08) in addition to Treatment-As-Usual (TAU). The intervention consisted of eight structured group sessions delivered over eight weeks, focusing on relapse prevention strategies, coping skills, and management of high-risk situations.
Treatment-As-Usual
ACTIVE COMPARATORParticipants in this arm received Treatment-As-Usual (TAU), which included standard rehabilitation services such as medical care, counselling, and psychosocial support provided by the treatment facility.
Interventions
The adapted Relapse Prevention Module (RPM-08) is a structured cognitive-behavioral intervention designed to reduce relapse risk among individuals with substance use disorders. It is based on relapse prevention principles and the stages of change model, focusing on identifying high-risk situations, recognizing early warning signs, and developing coping strategies. The intervention was culturally adapted for the Pakistani context and delivered in a group format. It consisted of eight structured sessions conducted over eight weeks. The sessions included psychoeducation, cognitive restructuring, emotional regulation, coping skills training, and relapse prevention planning. Cultural adaptations incorporated locally relevant examples, family-oriented perspectives, and context-specific coping strategies to enhance engagement and applicability.
Standard rehabilitation care provided by the treatment facility, including medical monitoring, counselling sessions, and psychosocial support services.
Eligibility Criteria
You may qualify if:
- Male participants diagnosed with moderate substance use disorder (DSM-5-TR)
- Aged 17 to 56 years
- Currently enrolled in a residential rehabilitation program
- Medically and psychologically stable to participate in group sessions
- Able to provide informed consent
You may not qualify if:
- Individuals diagnosed with severe psychiatric disorders (e.g., bipolar disorder, psychotic depression)
- Individuals with cognitive impairments affecting participation
- Individuals currently undergoing detoxification or taking medications that may influence treatment outcomes
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ghamkol Decent Rehab Center Addiction Treatment Center Lahore
Lahore, Punjab Province, 54000, Pakistan
Related Publications (2)
Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: Toward an integrative model of change. Journal of Consulting and Clinical Psychology. 1983;51(3):390-395.
BACKGROUNDMarlatt GA, Gordon JR. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. New York: Guilford Press; 1985.
BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Rabab Zahra, PhD Candidate (Psychology)
Universiti Utara Malaysia
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Masking Details
- This study was conducted as an open-label trial with no masking. Participants, care providers, and investigators were aware of group assignments due to the nature of the behavioral intervention.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctoral Researcher
Study Record Dates
First Submitted
April 20, 2026
First Posted
April 27, 2026
Study Start
January 4, 2024
Primary Completion
February 28, 2024
Study Completion
April 13, 2024
Last Updated
April 27, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared due to confidentiality and ethical considerations related to sensitive patient information. Data may be available from the principal investigator upon reasonable request for academic purposes.